Vyome Holdings, Inc.
HIND Healthcare Biotechnology
In the quarter to June 2026, revenue fell 46.0%, EPS grew 100.0% and free cash flow fell 195.0%, each against the same quarter a year earlier.
Follow HIND
Vyome Holdings, Inc. (HIND) Piotroski F-score
Vyome Holdings, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (1.00) |
| FY2024 | 5 | 0.00 |
| FY2023 | 5 | 0.00 |
| FY2020 | 5 | 3.00 |
| FY2019 | 2 | (2.00) |
| FY2018 | 4 | 0.00 |
| FY2017 | 4 | 0.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (260.50%) | (24.04%) | Fail | 0 |
| Positive operating cash flow | (3.75m) | (614.10k) | Fail | 0 |
| Rising return on assets | (260.50%) | (24.04%) | Fail | 0 |
| Cash flow above net income | 6.51m | 833.40k | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.99 | 0.05 | Pass | 1 |
| No new shares issued | 2,161,000 | 200 | Fail | 0 |
| Rising gross margin | 68.44% | 75.91% | Fail | 0 |
| Rising asset turnover | 0.08 | 0.04 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BCDA BioCardia, Inc. compare | 4 |
| HIND Vyome Holdings, Inc. | 4 |
| CLVSQ Clovis Oncology, Inc. compare | 3 |
| RVLP RVL Pharmaceuticals PLC compare | 3 |
| LPCN Lipocine Inc. compare | 1 |
| ICU SeaStar Medical Holding Corporation compare | — |
| CTXR Citius Pharmaceuticals, Inc. compare | — |
| ALLR Allarity Therapeutics, Inc. compare | — |
| KTTA Pasithea Therapeutics Corp. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover